Company: Bristol-Myers Squibb Company
Ticker: BMY
Form: 10-K
Filed: 2026-02-11
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Bristol-Myers Squibb Company's operating cash flow margin in fiscal year 2025?
Question Type: derived_ratio

Concept: NetCashProvidedByUsedInOperatingActivities
Revenues
Answer (Numeric): 29.37
Answer (Display): 29.37%
Unit: percent

Evidence:
[{"chunk_id": "200", "equivalent_chunk_ids": ["200"], "section": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "supports": ["numerator", "denominator"], "text": "Dollars in millions\nYear Ended December 31,\nCash Flows From Operating Activities:\nNet earnings/(loss)\n7,055\n8,933\n8,040\nAdjustments to reconcile net earnings/(loss) to net cash provided by operating activities:\nDepreciation and amortization, net\n4,011\n9,600\n9,760\nDeferred income taxes\n2,089\n3,288\nStock-based compensation\nImpairment charges\n1,098\n2,963\nDivestiture gains and royalties\n1,165\n1,119\nAcquired IPRD\n3,721\n13,373\nEquity investment (gains)/losses, net\nContingent consideration fair value adjustments\nOther adjustments\nChanges in operating assets and liabilities:\nReceivables\nInventories\nAccounts payable\nRebates and discounts\n1,484\nIncome taxes payable\n1,260\nOther\nNet cash provided by operating activities\n14,156\n15,190\n13,860\nCash Flows From Investing Activities:\nSale and maturities of marketable debt securities\n1,975\n1,122\nPurchase of marketable debt securities\n2,000\n1,774\nProceeds from sales of equity investments\nCapital expenditures\n1,311\n1,248\n1,209\nDivestiture and other proceeds\n1,071\n1,099\nAcquisition and other payments, net of cash acquired\n3,944\n21,821\n1,169\nNet cash provided by/(used in) investing activities\n4,132\n21,352\n2,295\nCash Flows From Financing Activities:\nProceeds from issuance of short-term debt obligations\n2,987\nRepayments of short-term debt obligations\n3,000\nOther short-term financing obligations, net\nProceeds from issuance of long-term debt\n5,740\n12,883\n4,455\nRepayments of long-term debt\n10,940\n2,873\n3,879\nRepurchase of common stock\n5,155\nDividends\n5,045\n4,863\n4,744\nStock option proceeds and other, net\nNet cash provided by/(used in) financing activities\n10,348\n5,127\n9,416\nEffect of exchange rates on cash, cash equivalents and restricted cash\nIncrease/(decrease) in cash, cash equivalents and restricted cash\n1,172\n2,194\nCash, cash equivalents and restricted cash at beginning of period\n10,347\n11,519\n9,325\nCash, cash equivalents and restricted cash at end of period\n10,218\n10,347\n11,519\nThe accompanying notes are an integral part of these consolidated financial statements.\nNote 1.\nACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS\nNature of Operations and Basis of Consolidation\nBristol-Myers Squibb Company (“BMS”, or “the Company”) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases."}]

Derivation: {"denominator": "revenue", "denominator_value": 48194.0, "format": "percentage", "numerator": "operating_cash_flow", "numerator_value": 14156.0, "op": "divide"}